Israel-Based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

Tel Aviv, Israel (ots/PRNewswire) -

Israeli startup Kanabo Research (http://www.kanaboresearch.com/),
which develops clinical solutions for extraction and vaporization of
medical cannabis, announces it is entering an agreement with
Constance Therapeutics, a US-based medical cannabis extraction
company.

(Photo: https://mma.prnewswire.com/media/682136/Constance_Therapeu
tics_and_Kanabo_Research.jpg )

According to the agreement, both companies will operate in the EU
to establish a cannabis cultivation farm as well as manufacturing
capabilities of cannabis active compounds - THC and CBD - to be used
in an array of medical treatments and chronic ailments such as
insomnia, PTSD and chronic pain. Simultaneously, Constance
Therapeutics will market Kanabo Research's solutions in the US market
where Constance Therapeutics has been operating since 2008.

"We are happy to join hands with a medical cannabis market leader
like Constance Therapeutics which will allow us to strengthen our
presence in the American market," said Avihu Tamir, co-founder and
CEO of Kanabo Research. "At the same time, we are operating to locate
global opportunities in light of the fact that many countries are
asking to join the medical cannabis revolution. The move will allow
us to accelerate our manufacturing pace - especially important now
because of the delays in medical cannabis export approvals in Israel
- and will provide us with an excellent base for additional
operations in other markets, primarily European markets."

Kanabo Research has seen significant momentum in the last few
months. Recently, the company received initial approvals from
Israel's Ministry of Health to use cannabis with its proprietary
VapePod vaporizer. Similarly, the company has commenced pre-clinical
trials of Kanabo's proprietary formulations that focus on sleep
disorders and in the future for patients suffering from PTSD.

"Constance Therapeutics is excited to partner with Kanabo
Research. Kanabo is similarly focused on research and evidence-based
solutions in the cannabis space as we are at Constance Therapeutics,"
said Constance Finley, Founder and CEO of Constance Therapeutics.
"The standardization Constance Therapeutics pioneered in extracts,
Kanabo matches in its precision dosing hardware. This is a natural
fit and extends each company's expertise into new territories and
most importantly, offers emerging cannabis customers the most
innovative and enjoyable option."

About Kanabo Research

Israeli Startup Kanabo Research conducts research and development
of medical cannabis extraction and vaporization solutions. Kanabo's
vaporization device - VapePod - allows patients to inhale natural
cannabis and increase effectiveness without any smoke. Similarly, the
device, which is patent protected, lets patients monitor the dosage
precisely and over time. Kanabo's extraction pods, which are based on
extensive medical trials and in cooperation with leading doctors in
Israel and around the world, provide treatments that target central
nervous system disorders affecting sleep, anxiety and chronic pain.

The company was founded in 2016 by CEO, Avihu Tamir, and COO,
David Sack. Among the partners and investors are David Tsur,
Co-founder and former Chief Executive Officer of Kamada Ltd. (NASDAQ:
KMDA). Dr. Doron Friedman, CTO with over 25 years' experience as a
biomedical entrepreneur and executive. Dr. Friedman is the inventor
of Bausch and Lomb's Lotemax eye drops, and holds over 80 patents.
And Dr. Nachshon Knoler, world-renowned neurosurgeon, currently
Director of the Department of Neurosurgery at Sheba Medical Center in
Tel-Hashomer, Israel.

Kanabo Research operates in the Science Park at Weitzman
Institute. Visit: http://www.kanaboresearch.com/

About Constance Therapeutics

Constance Therapeutics is a vertically-integrated medicinal
cannabis company producing standardized, science-based whole-plant
cannabis extracts. These extracts fill the gap between traditional
pharmaceuticals and commonplace cannabis products, providing much
needed additional treatment options for physicians and their
patients.

Constance Therapeutics' extracts are derived from fully trimmed,
female, unfertilized cannabis flowers of plants with known genetics
using certified organic, pharmaceutical-grade ethanol via a
highly-controlled, quantitatively defined and patented process based
on solid scientific and engineering principles. Extracts are
systematically third-party tested and routinely cross-tested in the
industry's most respected laboratories. Since 2008, the company has
employed stringent, science-based processes and standards to ensure
the highest quality and consistency.

Headquartered in San Francisco, CA, and recently permitted under
the new California regulations, Constance Therapeutics' cannabis
extracts have historically been available exclusively for therapeutic
use by registered California patients under Proposition 215 and
California Senate Bill 420. With the new California regulations, in
addition to continuing to serve their physician referred medical
patients, Constance Therapeutics will distribute their products
throughout the state for sale in licensed dispensaries. Additionally,
Constance Therapeutics is underway with globally licensing their
patented formulations for sale in legal markets across the world. For
further information, visit http://www.constancetherapeutics.com.

ots Originaltext: Constance Therapeutics and Kanabo Research
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Gil Kraiem
gil@Pitch-Media.com
+972-50-5703090

Original-Content von: Constance Therapeutics and Kanabo Research, übermittelt durch news aktuell